Equities research analysts predict that Biopharmx Corp (NYSE:BPMX) will report $30,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Biopharmx Corp’s earnings, with the highest sales estimate coming in at $40,000.00 and the lowest estimate coming in at $10,000.00. Biopharmx Corp also posted sales of $30,000.00 in the same quarter last year. The company is scheduled to announce its next earnings results on Tuesday, June 13th.
On average, analysts expect that Biopharmx Corp will report full-year sales of $30,000.00 for the current fiscal year, with estimates ranging from $30,000.00 to $3 million. For the next fiscal year, analysts anticipate that the business will post sales of $6.74 million per share, with estimates ranging from $50,000.00 to $20 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Biopharmx Corp.
Several equities analysts recently commented on the stock. ValuEngine upgraded shares of Biopharmx Corp from a “strong sell” rating to a “sell” rating in a report on Wednesday. Roth Capital set a $3.00 price target on shares of Biopharmx Corp and gave the company a “buy” rating in a report on Thursday, February 9th.
ILLEGAL ACTIVITY NOTICE: “$30,000.00 in Sales Expected for Biopharmx Corp (BPMX) This Quarter” was published by BBNS and is owned by of BBNS. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/30000-00-in-sales-expected-for-biopharmx-corp-bpmx-this-quarter/836577.html.
Biopharmx Corp (NYSE:BPMX) traded down 5.3420% on Friday, reaching $0.6255. The company had a trading volume of 2,129,655 shares. The stock’s 50 day moving average price is $0.63 and its 200-day moving average price is $0.47. Biopharmx Corp has a 12-month low of $0.19 and a 12-month high of $1.22. The stock’s market capitalization is $42.36 million.
Biopharmx Corp Company Profile
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with our FREE daily email newsletter.